A novel prognostic score of recurrence for endometrial cancer patients with staging surgery
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.A new endometrial tumor-related (ETR) score effectively predicts endometrial cancer recurrence. This scoring system, using inflammatory markers, tumor markers, and histology, offers comparable accuracy to current staging systems.
Area Of Science
- Oncology
- Biomarkers
- Cancer Prognostics
Background
- Growing evidence links inflammatory markers to cancer prognosis.
- Existing inflammatory indicators for cancer have limited predictive accuracy.
- Need for improved prognostic tools in endometrial cancer management.
Purpose Of The Study
- Develop a novel scoring system for endometrial cancer recurrence prediction.
- Integrate inflammatory markers, tumor markers, and histological data.
- Enhance prognostic accuracy beyond current methods.
Main Methods
- Utilized data from endometrial cancer patients undergoing surgery (2007-2020).
- Developed the endometrial tumor-related (ETR) score based on cutoff values.
- Included lymph node metastasis, myometrial invasion, CEA, D-dimer, and WBC count variations.
Main Results
- Positive lymph node metastasis, myometrial invasion, high CEA, high D-dimer, and significant WBC count changes predicted recurrence.
- The ETR score demonstrated comparable sensitivity and specificity to the FIGO staging system.
- ETR score showed significant association with recurrence in patients with complete tumor removal.
Conclusions
- The ETR score serves as a significant prognostic marker for endometrial cancer recurrence.
- This new system aids in predicting outcomes for patients post-staging surgery.
- ETR score offers a valuable tool for personalized endometrial cancer management.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.